Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

NCT ID: NCT01336751

Last Updated: 2011-04-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 212 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2001-07-31
• Study Completion Date: 2002-12-31

Brief Summary

Study Primary Objectives:

To compare glycemic control, as measured by hemoglobin A1c (A1C), between insulin glargine and 75% insulin lispro protamine suspension/25% insulin lispro as add-on therapies in subjects who failed oral combination therapy with sulfonylurea and metformin.

Study Secondary Objectives :

To compare the following measures between subjects receiving insulin glargine or 75% insulin lispro protamine suspension/25% insulin lispro:

• Incidence of hypoglycemia
• Change in weight
• Change in serum lipid profile
• Percentage of subjects achieving A1C levels ≤7%

Detailed Description

The planned duration of enrollment is 6 months. The study consists of 2 weeks screening phase and a study period that was planned to be 24 weeks.

Conditions

Diabetes Mellitus, Type 2

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Insulin glargine

Lantus (insulin glargine) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by Self-monitoring blood glucose (SMBG).

The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator.

Group Type: EXPERIMENTAL

Insulin glargine

Intervention Type: DRUG

solution for subcutaneous injection

Lispro mix

Humalog Mix 75/25 (lispro mix) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by self-monitoring blood glucose (SMBG).

The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator.

Group Type: ACTIVE_COMPARATOR

75% insulin lispro protamine suspension and 25 % insulin lispro injection

Intervention Type: DRUG

suspension for subcutaneous injection

Interventions

Insulin glargine

solution for subcutaneous injection

Intervention Type: DRUG

75% insulin lispro protamine suspension and 25 % insulin lispro injection

suspension for subcutaneous injection

Intervention Type: DRUG

Other Intervention Names

Lantus; Humalog

Eligibility Criteria

Inclusion Criteria

• Patients must have given their signed informed consent.
• Males or females between 18 and 79 years of age.
• Diagnosis of type 2 diabetes mellitus for at least one year.
• Patients must have had continuous oral hypoglycemic treatment for at least three months using dosing of: at least half maximally labeled dose of sulfonylurea + at least 1000 mg metformin daily.
• HBA1C ≥ 8 % and ≤11 %, inclusive, as measured at screening (visit 1).
• Patients must have BMI of > 25 kg/m2 at baseline
• Willingness to accept, and demonstrate ability to inject insulin glargine or 75% insulin lispro protamine suspension and 25% insulin lispro injection therapy.
• Ability and willingness to perform SMBG profiles using a plasma glucose meter at least twice a day.
• Patients must be able to understand and willing to adhere to and be compliant with the study protocol

Exclusion Criteria

• Patients, who have had stroke, MI, coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA) or angina pectoris within the last 12 months.
• Patients with congestive heart failure requiring pharmacological treatment.
• Patients on non-selective beta blockers (including ocular).
• Patients with impaired renal function, as shown by but not limited to serum creatinine ≥ 1.5 mg/dl (133μmol/L) for males, or ≥ 1.4 mg/dl (124 μmol/L) for females.
• Patients with acute infections.
• Patients with diagnosis of dementia.
• Treatment with systemic steroids or large doses of inhaled steroids.
• Patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis.
• Patients with planned radiological examinations requiring administration of contrasting agents.
• Clinical evidence of active liver disease, or serum ALT 2.5 times the upper limit of the normal range.
• Patients with history of hypoglycemia unawareness.
• Pregnant or lactating females.
• Failure to use adequate contraception (women of current reproductive potential only).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 79 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: lead

Responsible Party

sanofi-aventis

Principal Investigators

Medical Affairs

Role: STUDY_DIRECTOR

Sanofi

Locations

Sanofi-Aventis Administrative Office

Bridgewater, New Jersey, United States

Countries

United States

Other Identifiers

HOE901_4021

Identifier Type: -

Identifier Source: org_study_id